Understanding Spitz Melanoma: A Comprehensive Guide

I. Introduction to Spitz Melanoma

Spitz melanoma, historically and sometimes still referred to as melanoma di spitz, represents a distinct and often diagnostically challenging subtype of melanoma. Named after Dr. Sophie Spitz who first described 'Spitz nevi' in 1948, Spitz melanoma occupies a complex spectrum between benign Spitz nevi and conventional malignant melanoma. It is characterized by its unique histological features, including large epithelioid or spindle-shaped melanocytes, and often presents in a younger demographic, though it can occur at any age. Unlike more common forms, its clinical behavior can be unpredictable, sometimes behaving indolently like a nevus and other times aggressively like a classic melanoma, making expert pathological review paramount.

In terms of prevalence, Spitz melanoma is considered rare. While comprehensive Hong Kong-specific data on Spitz melanoma is limited due to its rarity, melanoma overall accounts for a smaller but significant proportion of skin cancers in Asian populations compared to Western countries. For context, data from the Hong Kong Cancer Registry indicates that melanoma constitutes approximately 1-2% of all registered cancer cases. Within this melanoma cohort, the acral subtype, such as melanoma acrale (melanoma on palms, soles, or under nails), is notably more common in Asian populations, including Hong Kong Chinese, than the superficial spreading type predominant in Caucasians. Spitz melanoma is rarer still, representing only a small fraction of all melanomas diagnosed. Its relative rarity underscores the importance of specialist centers for accurate diagnosis and management, as it can be mistaken for more common benign lesions or other melanoma subtypes.

II. Causes and Risk Factors

The precise etiology of Spitz melanoma remains an area of active research, but several key factors are believed to contribute to its development. Unlike conventional melanoma, where cumulative sun exposure is a major driver, the role of ultraviolet (UV) radiation in Spitz melanoma is less clear-cut and may be more nuanced.

A. Genetic predisposition

Genetic alterations are at the core of Spitz melanoma pathogenesis. A hallmark discovery has been the identification of specific genomic rearrangements and fusions, particularly involving the ALK, ROS1, NTRK1, BRAF, and RET genes. These fusions lead to constitutive activation of kinase signaling pathways that drive uncontrolled cell growth. For instance, an ALK fusion is found in a significant subset of Spitz tumors. This is distinct from the BRAF V600E mutations common in conventional melanomas. There is also no strong evidence of a hereditary syndrome specifically for Spitz melanoma, unlike familial atypical multiple mole melanoma (FAMMM) syndrome. However, individuals with a personal or family history of atypical moles or melanoma may have a generally increased risk for all melanoma subtypes.

B. Sun exposure and UV radiation

The relationship between sun exposure and Spitz melanoma is complex and not as directly causal as with other melanomas. While classic melanomas often arise on chronically sun-exposed skin, Spitz melanomas frequently occur on the limbs, trunk, and head and neck of children and young adults, areas that may have had intermittent rather than chronic exposure. Some studies suggest that UV radiation may act as a co-factor or trigger in genetically predisposed individuals, potentially causing additional mutations that push a borderline Spitz tumor toward malignancy. However, it is crucial to note that Spitz melanomas can also arise in sun-protected areas, indicating that alternative pathways are involved.

C. Other potential risk factors

Other risk factors are less defined. The young age of onset for many cases suggests that developmental factors may play a role. Immunosuppression is a known risk factor for melanoma in general and may also apply to the Spitz subtype. It is important to differentiate the risk profile from that of melanoma acrale lentigginoso palmo mano (acral lentiginous melanoma of the palm and hand), which, as seen in Hong Kong and other Asian populations, shows no clear association with UV exposure and is thought to be driven by factors like chronic mechanical stress or genetic susceptibility unrelated to sun.

III. Symptoms and Diagnosis

Recognizing Spitz melanoma based on clinical appearance alone is exceptionally difficult, even for experienced dermatologists, as it often mimics benign lesions.

A. Recognizing the signs of Spitz Melanoma

Clinically, a Spitz melanoma may present as a rapidly growing, dome-shaped, pink (amelanotic) or pigmented (tan, brown, black) papule or nodule. It is often solitary and can occur anywhere on the body. The classic "starburst" pattern seen on dermoscopy in some Spitz nevi may be irregular or absent in melanomas. Warning signs that should prompt further investigation include rapid growth, change in color or shape, bleeding, ulceration, or itching in a lesion, especially in a child or young adult. However, many are asymptomatic. This contrasts with the typical presentation of a melanoma acrale, which often begins as a dark, irregularly bordered streak or patch on the sole, palm, or under a nail (subungual), frequently overlooked until later stages.

B. Diagnostic methods (biopsy, imaging)

The cornerstone of diagnosis is a complete excisional biopsy with narrow margins, removing the entire lesion for pathological examination. A shave or punch biopsy is generally discouraged for suspected Spitz tumors due to the risk of sampling error. Histopathological analysis by a dermatopathologist with expertise in melanocytic lesions is critical. Key features assessed include symmetry, maturation, cytologic atypia, mitotic rate, and presence of ulceration. In challenging cases, ancillary tests are invaluable:

• Immunohistochemistry (IHC): Markers like HMB-45, Ki-67 (proliferation index), and p16 can help assess malignancy.
• Molecular Genetic Testing: Fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS) panels can detect characteristic gene fusions (e.g., ALK) or the absence of common melanoma mutations, supporting a diagnosis of Spitz melanoma.

For staging, if the diagnosis is confirmed as melanoma, imaging such as ultrasound of regional lymph nodes, CT, PET-CT, or MRI may be used to assess for metastasis, guided by tumor thickness and other risk factors.

C. Differential diagnosis: distinguishing from other skin lesions

This is the greatest challenge. The main differentials include:

• Spitz Nevus: The benign counterpart. Distinction relies heavily on histology and sometimes molecular profiling.
• Conventional Melanoma: Lacks the specific Spitzoid cytomorphology and often has different genetic drivers (BRAF, NRAS mutations).
• Pyogenic Granuloma: A benign vascular growth that can bleed and grow quickly, often confused with amelanotic Spitz melanoma.
• Dermatofibroma: A firm, benign nodule.
• Other Melanoma Subtypes: It is vital to differentiate Spitz melanoma from a melanoma acrale lentigginoso palmo mano, which has a distinct clinical setting (acral sites), histology (lentiginous growth pattern), and often a worse prognosis due to later diagnosis.

IV. Treatment Options

The management of Spitz melanoma follows principles similar to other melanomas but is tailored based on its unique biological behavior and the patient's age.

A. Surgical excision

Wide local excision (WLE) is the primary and curative treatment for localized disease. The recommended surgical margin is determined by the Breslow thickness of the tumor, as per standard melanoma guidelines (e.g., 1 cm for tumors ≤1.0 mm, 2 cm for >2.0 mm). Achieving clear histological margins is the goal. For lesions on cosmetically or functionally sensitive areas like the face, a multidisciplinary approach involving a dermatologic surgeon or plastic surgeon is essential to balance oncologic safety with aesthetic and functional outcomes.

B. Sentinel lymph node biopsy

Sentinel lymph node biopsy (SLNB) is a standard staging procedure for conventional melanomas beyond a certain thickness (typically >0.8 mm) or with other high-risk features. Its role in Spitz melanoma is more controversial, especially in children. A positive SLNB indicates regional metastasis and upstages the disease. However, some studies suggest that children with Spitz melanoma and a positive SLNB may still have an excellent prognosis, leading to debates about the prognostic significance and therapeutic implications of SLNB in this specific context. The decision is made individually, considering patient age, tumor characteristics, and family preferences, after thorough discussion with an oncologist and surgeon.

C. Adjuvant therapies (if needed)

For patients with high-risk features (e.g., thick tumors, ulceration, positive lymph nodes) or metastatic disease, adjuvant systemic therapy may be recommended. The landscape has been revolutionized by targeted therapies and immunotherapy:

• Targeted Therapy: If molecular testing reveals a targetable fusion (e.g., ALK, NTRK, ROS1), drugs like ALK inhibitors (crizotinib, alectinib) or NTRK inhibitors (larotrectinib, entrectinib) can be highly effective.
• Immunotherapy: Checkpoint inhibitors such as pembrolizumab and nivolumab (anti-PD-1) have shown efficacy in advanced melanoma, including some Spitz melanomas, by helping the immune system recognize and attack cancer cells.
• Radiotherapy: May be used for local control of unresectable metastases or as adjuvant treatment after lymph node dissection.

These treatments are typically managed by a clinical oncologist specializing in melanoma.

V. Prognosis and Follow-up

The prognosis of Spitz melanoma is generally more favorable than that of conventional melanoma of equivalent thickness, particularly in children. However, it is not uniformly benign, and aggressive cases do occur.

A. Factors affecting prognosis

Key prognostic factors include:

Factor	Favorable Prognosis	Unfavorable Prognosis
Age	Younger age (especially	Older age (adults)
Tumor Thickness (Breslow)	Thin (	Thick (>4 mm)
Ulceration	Absent	Present
Mitotic Rate	Low (	High (>1/mm²)
Lymph Node Status	Negative	Positive

The presence of specific genetic fusions may also correlate with behavior, though research is ongoing. It is worth contrasting this with the prognosis of melanoma acrale, which, in Hong Kong populations, is often diagnosed at a more advanced stage due to location, leading to a generally poorer prognosis compared to early-detected Spitz melanoma.

B. Importance of regular skin exams

Long-term follow-up is essential. This includes:

• Self-Examination: Patients and parents should be educated on monthly skin self-exams to monitor for new or changing lesions.
• Clinical Surveillance: Regular follow-up with a dermatologist (e.g., every 3-12 months depending on risk) for full-body skin examinations.
• Lymph Node Checks: Palpation of regional lymph node basins.
• Imaging: For high-risk cases, periodic imaging may be recommended to screen for distant recurrence.

C. Living with Spitz Melanoma

A diagnosis can cause significant anxiety. Support from healthcare teams, patient support groups, and mental health professionals is beneficial. Sun protection remains a universal recommendation—using broad-spectrum sunscreen, wearing protective clothing, and seeking shade—to reduce overall skin cancer risk and protect the surgical scar. Patients should maintain a healthy lifestyle and be vigilant about any new symptoms.

VI. Latest Research and Advancements

The field of Spitz melanoma research is dynamic, focusing on refining diagnosis and expanding treatment options.

A. New treatment approaches

Beyond established targeted therapies, research is exploring:

• Neoadjuvant Therapy: Using targeted drugs or immunotherapy before surgery to shrink tumors and assess response, potentially improving surgical outcomes and long-term survival.
• Combination Therapies: Pairing different targeted agents or combining targeted therapy with immunotherapy to overcome resistance.
• Tumor-Agnostic Therapies: Drugs like NTRK inhibitors are approved based on the genetic marker (NTRK fusion) regardless of cancer type, benefiting Spitz melanoma patients with this alteration.

B. Ongoing clinical trials

Clinical trials are crucial for advancing care. Patients, especially those with advanced disease, may consider enrolling in trials investigating:

• New-generation ALK/NTRK/ROS1 inhibitors.
• Novel immunotherapeutic agents or combinations.
• Adaptive therapy strategies based on minimal residual disease detection.

International and regional centers in Asia, including those in Hong Kong collaborating within global networks, may offer trials relevant to melanoma patients. It is important to discuss trial eligibility with an oncologist.

VII. Hope and Prevention

The journey from diagnosing a challenging lesion like Spitz melanoma to effective management embodies the progress in dermatology and oncology. While Spitz melanoma is rare, advancements in molecular diagnostics have dramatically improved our ability to distinguish it from its benign mimics and other subtypes like melanoma di spitz or the more prevalent melanoma acrale lentigginoso palmo mano. This precision directly informs treatment, allowing for therapies tailored to the tumor's genetic blueprint. Hope lies in this era of personalized medicine, where even rare cancers have identifiable targets. Prevention, though less defined than for sun-related melanomas, centers on awareness. Recognizing that any new, changing, or unusual skin growth warrants professional evaluation is critical. Public health efforts in diverse regions like Hong Kong should emphasize skin awareness across all melanoma subtypes—from the sun-exposed sites to the palms, soles, and under nails. Through vigilance, expert care, and ongoing research, the outlook for individuals diagnosed with Spitz melanoma continues to improve, highlighting the power of medical science in addressing even the most uncommon diseases.